Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Puma Biotechnology (PBYI)

Puma Biotechnology (PBYI)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
3.01 +0.08 (+2.73%) 04/02/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 3.00 -0.01 (-0.33%) 16:14 ET
Quote Overview for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.88
Day High
3.03
Open 2.89
Previous Close 2.93 2.93
Volume 259,100 259,100
Avg Vol 379,710 379,710
Stochastic %K 9.05% 9.05%
Weighted Alpha -36.95 -36.95
5-Day Change -0.12 (-3.83%) -0.12 (-3.83%)
52-Week Range 2.22 - 6.05 2.22 - 6.05
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,360
  • Shares Outstanding, K 49,611
  • Annual Sales, $ 230,470 K
  • Annual Income, $ 30,280 K
  • EBIT $ 31 M
  • EBITDA $ 42 M
  • 60-Month Beta 1.34
  • Price/Sales 0.64
  • Price/Cash Flow 3.47
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 116.55% ( +7.48%)
  • Historical Volatility 74.44%
  • IV Percentile 43%
  • IV Rank 21.00%
  • IV High 499.61% on 06/20/24
  • IV Low 14.72% on 08/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 56
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 2,057
  • Open Int (30-Day) 2,687

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.01
  • Number of Estimates 3
  • High Estimate 0.00
  • Low Estimate -0.02
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +90.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.88 +4.51%
on 04/02/25
Period Open: 3.58
3.75 -19.73%
on 03/06/25
-0.57 (-15.92%)
since 02/28/25
3-Month
2.69 +11.90%
on 02/11/25
Period Open: 3.12
4.06 -25.86%
on 01/07/25
-0.11 (-3.53%)
since 01/02/25
52-Week
2.22 +35.28%
on 09/06/24
Period Open: 5.28
6.05 -50.29%
on 04/09/24
-2.27 (-42.99%)
since 04/02/24

Most Recent Stories

More News
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

Puma Biotechnology PBYI reported fourth-quarter 2024 adjusted earnings of 43 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company reported adjusted...

FOLD : 7.99 (+0.50%)
IMCR : 29.43 (+2.79%)
PBYI : 3.01 (+2.73%)
PCRX : 24.89 (+3.41%)
Puma Biotech: Q4 Earnings Snapshot

Puma Biotech: Q4 Earnings Snapshot

PBYI : 3.01 (+2.73%)
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational pipeline candidates, VIR-5818 and VIR-5500, for the treatment of various solid tumors.While...

CTMX : 0.6087 (+4.95%)
PBYI : 3.01 (+2.73%)
CSTL : 20.19 (+2.07%)
VIR : 6.48 (+4.85%)
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

Shares of CorMedix CRMD rose nearly 30% on Tuesday after management announced fourth-quarter and full-year 2024 preliminary sales figures.CorMedix’s Preliminary Sales Figures Beat EstimatesCorMedix reported...

CTMX : 0.6087 (+4.95%)
PBYI : 3.01 (+2.73%)
CSTL : 20.19 (+2.07%)
CRMD : 6.30 (+3.79%)
Geron Stock Rallies More Than 60% in a Year: Here's Why

For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic syndromes...

PBYI : 3.01 (+2.73%)
CSTL : 20.19 (+2.07%)
GERN : 1.5900 (+7.43%)
HALO : 63.02 (+1.86%)
Here's Why You Should Consider Buying Atara Biotherapeutics Stock

Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy company with several near-term catalysts. This Zacks Rank #2 (Buy) company boasts a pipeline of differentiated therapies across a...

PBYI : 3.01 (+2.73%)
CSTL : 20.19 (+2.07%)
ATRA : 6.13 (+2.00%)
HALO : 63.02 (+1.86%)
Best Momentum Stocks to Buy for January 6th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 6:NRx Pharmaceuticals, Inc. NRXP: This bio-pharmaceutical company has a Zacks Rank #1 and...

PDEX : 55.19 (+7.37%)
PBYI : 3.01 (+2.73%)
NRXP : 2.0100 (+3.61%)
Best Value Stocks to Buy for January 6th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, January 6:Ashford Hospitality Trust, Inc. AHT: This real estate investment trust carries a Zacks Rank...

CWD : 0.5430 (+0.50%)
PBYI : 3.01 (+2.73%)
AHT : 7.07 (-1.39%)
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why

Shares of Puma Biotechnology, Inc. PBYI have rallied 24% in the past three months against the industry’s decline of 9.7%.The company’s sole marketed product, Nerlynx (neratinib), is approved for treating...

IMCR : 29.43 (+2.79%)
PBYI : 3.01 (+2.73%)
RHHBY : 39.3700 (-4.16%)
SPRO : 0.7060 (+1.73%)
Best Momentum Stocks to Buy for December 24th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 24:Puma Biotechnology, Inc. PBYI: This biopharmaceutical company has a Zacks Rank #1 and...

DDS : 364.04 (+0.71%)
NJR : 49.56 (+0.92%)
PBYI : 3.01 (+2.73%)

Business Summary

Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also...

See More

Key Turning Points

3rd Resistance Point 3.22
2nd Resistance Point 3.12
1st Resistance Point 3.07
Last Price 3.01
1st Support Level 2.92
2nd Support Level 2.82
3rd Support Level 2.77

See More

52-Week High 6.05
Fibonacci 61.8% 4.59
Fibonacci 50% 4.14
Fibonacci 38.2% 3.69
Last Price 3.01
52-Week Low 2.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades